½ÃÀ庸°í¼­
»óǰÄÚµå
1547885

¼¼°èÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Pharmacovigilance and Drug Safety Software Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 171 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 2¾ï 157¸¸ ´Þ·¯¿¡¼­ 2032³â 3¾ï 7,939¸¸ ´Þ·¯¿¡ À°¹ÚÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2024-2032³â ¿¬Æò±Õ 7.28%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î´Â Á¦Ç° ¾ÈÀü À§ÇèÀ» ÁÙÀ̰í, ±ÔÁ¤ Áؼö¸¦ ´Þ¼ºÇϸç, ¾à¹°°¨½Ã ÇÁ·Î¼¼½ºÀÇ È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â ¾ÖÇø®ÄÉÀ̼ÇÀÔ´Ï´Ù. ö¼ö ¿øÀÎÀ» ½Äº°Çϰí ÇâÈÄ ºÒÇÊ¿äÇÑ »ç°ÇÀ» ¾ïÁ¦ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î´Â ¾ÈÀü ¹× ±ÔÁ¦ º¸°í ¹× °ü¸®, Á¤ºÎ ¹× °í°´¿¡ ´ëÇÑ ÀϰüµÈ »óȲ º¸°í¸¦ ÃßÀûÇÏ°í ±â·Ï¿¡ ´ëÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϸç, ÀǾàǰÀÇ Áøº¸¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» ±â¼úÇÕ´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î´Â ±ÔÁ¦ ±â°ü, Á¦¾à»ç ¹× ÀÇ·á Àü¹®°¡µéÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÚµ¿È­¿Í µðÁöÅÐÈ­´Â ÀÓ»ó ¿¬±¸¸¦ Æ÷ÇÔÇÑ ¸ðµç ºÎ¹®¿¡¼­ Áõ°¡ÇÏ´Â Ãß¼¼ÀÔ´Ï´Ù. »õ·Î¿î Ä¡·á¹ý°ú ½Å¾à¿¡ ´ëÇÑ ¿¬±¸°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. »ý¸íÀ» À§ÇùÇÏ´Â °¨¿°¼º ÁúȯÀº »ç¸Á·ü°ú ÀÌȯÀ²¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡¸ç, ÇØ´ç ±¹°¡¿¡ ¸·´ëÇÑ °æÁ¦Àû ºÎ´ãÀ» ¾È°ÜÁÖ°í ÀÖ½À´Ï´Ù. ÇöÀç »ç¿ë °¡´ÉÇÑ ÀǾàǰÀº ´ëºÎºÐÀÇ Áúº´¿¡ ´ëÇØ ºÒÃæºÐÇϸç, »õ·Î¿î Ä¡·á¹ý °³¹ßÀÌ ½Ã±ÞÇÑ »óȲÀÔ´Ï´Ù. ¿¬±¸ ½ÃÀÛºÎÅÍ Á¾·á±îÁö, ¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î´Â ÀÓ»ó ¿¬±¸¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î´Â Á¤º¸¸¦ ÇÑ °÷¿¡ ¸ð¾Æ °ü¸® ºÎ´ã°ú ¾÷¹«·®À» ÁÙÀ̰í, ¸ðµç ¿¬±¸ °£ÀÇ Çù¾÷À» ÃËÁøÇÏ¿© ÀÓ»ó½ÃÇè ¶ó¿îµå¸¦ Áö¿øÇÕ´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î¸¦ µµÀÔÇÏ¸é ¿¬±¸ ¶Ç´Â ÀÓ»ó½ÃÇè µ¥ÀÌÅ͸¦ À¯Áö, °èȹ, ½ÇÇà, °ü¸®, º¸°íÇÏ´Â ¼Óµµ¿Í È¿À²¼ºÀÌ Å©°Ô Çâ»óµË´Ï´Ù. ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º Á¶»ç ¼ÒÇÁÆ®¿þ¾î´Â ÀÓ»ó ¿¬±¸ ¿µ¿ª¿¡¼­ ½ÃÇè µ¥ÀÌÅÍ ¼öÁý, ½ÃÇè °á°ú ÃßÀû, ½ºÄÉÁÙ¸µ, ¸ð´ÏÅ͸µ ¹× ±âŸ ¿©·¯ °¡Áö¸¦ ¼öÇàÇÒ ¼ö ÀÖ´Â ÈǸ¢ÇÑ µµ±¸ÀÔ´Ï´Ù. ¸¹Àº ÀÌÁ¡ÀÌ Àֱ⠶§¹®¿¡ ´õ ¸¹Àº ÀÓ»ó ¿¬±¸°¡ ÀÌ ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¿© ±Ã±ØÀûÀ¸·Î ½ÃÀåÀÇ °ÇÀüÇÑ ¼ºÀåÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ÀÌÁ¡À» ¾òÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ ÇâÈÄ ±âȸ¸¦ ÅëÇØ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»ó °í°´À» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ÀúÈñ¿¡°Ô ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î - »ê¾÷ ºÐ¼®

  • ¼Ò°³ : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀÚÀç ºÐ¼®
    • ¿øÀÚÀç ¸®½ºÆ®
    • ¿øÀÚÀç Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀÚÀç °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå ºÐ¼® : ±â´Éº°

  • ±â´Éº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ±â´Éº° ºÐ¼®
  • Áõ·Ê µ¥ÀÌÅÍ ¼öÁý°ú °ü¸®
  • À¯ÇØ »ç·Ê º¸°í¿Í ºÐ¼®
  • ½ÅÈ£ °ËÃâ°ú ±âŸ ¾ÈÀü¼º ¸®½ºÅ© Æò°¡

Á¦6Àå ¾à¹°°¨½Ã¿Í µå·¯±× ¼¼ÀÌÇÁƼ ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå ºÐ¼® : ¹èÆ÷ ¹æ½Äº°

  • ¹èÆ÷ ¹æ½Äº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¹èÆ÷ ¹æ½Äº° ºÐ¼®
  • ¿ÂÇÁ·¹¹Ì½º
  • ¿Âµð¸Çµå

Á¦7Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾ ¿ëµµº° ºÐ¼®
  • ÀÇ·á ±â¾÷(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷)
  • CRO/BPO ¶Ç´Â PV ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ(¾Æ¿ô¼Ò½ÌÀÇ °æ¿ì)
  • ±âŸ

Á¦8Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ±â¾÷ °æÀï »óȲ

  • ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù·Â/ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • IQVIA
  • Accenture
  • Cognizant
  • Laboratory Corporation Of America Holdings
  • IBM
  • ArisGlobal
  • ICON Plc.
  • Capgemini
  • Oracle
  • Parexel International Corporation
ksm 24.10.02

The global demand for Pharmacovigilance and Drug Safety Software Market is presumed to reach the market size of nearly USD 379.39 Million by 2032 from USD 201.57 Million in 2023 with a CAGR of 7.28% under the study period 2024-2032.

Pharmacovigilance and drug safety software is an application that reduces product safety risk, achieves compliance, and improves the efficiency of pharmacovigilance processes. It identifies the cause of withdrawal and helps to inhibit unnecessary future events. Software reports and manages safety and regulation, consistently track status reports to governments and clients, enable access to records, and medicine advancement expertise. The software is approved by regulating agencies, pharmaceutical companies, and medical professionals.

MARKET DYNAMICS

Automation and digitalization is an increasing trend in every sector, including clinical research. Growing research on new therapies and drugs is augmenting the growth of the market. Infectious life-threatening diseases have a massive effect in terms of mortality and morbidity and oblige substantial economic trouble on affected countries. Currently, available drugs are insufficient for the majority of these diseases, and there is an urgent need for new treatments. From a research start to close out, pharmacovigilance software plays a crucial role in clinical research. This software help reduce the administrative burdens and workloads by consolidating information in a familiar location, supports the trial round by facilitating the cooperation between all the researches. Incorporation of this software dramatically enhances the speed and efficiency in maintaining, planning, performing, managing, and reporting of the research or study data. Pharmacovigilance and Drug Safety Softwares are great tools in the clinical research domain to collect trial data to track study performance, schedule, monitor, and many more. Due to a massive bundle of advantages, it is predicted that more and more clinical research will use this software to grab the benefits that will eventually result in the healthy growth of the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmacovigilance and Drug Safety Software. The growth and trends of Pharmacovigilance and Drug Safety Software industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmacovigilance and Drug Safety Software market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Functionality

  • Case Data Collection and Management
  • Adverse Event Reporting and Analysis
  • Signal Detection and Other Safety Risk Assessment

By Delivery Mode

  • On Premise
  • On Demand

By End Use

  • Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
  • CROs/BPOs or PV Service Providers When Outsourced.
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmacovigilance and Drug Safety Software market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacovigilance and Drug Safety Software market include IQVIA, Accenture, Cognizant, Laboratory Corporation Of America Holdings, IBM, ArisGlobal, ICON Plc., Capgemini, Oracle, Parexel International Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Functionality
    • 3.7.2 Market Attractiveness Analysis By Delivery Mode
    • 3.7.3 Market Attractiveness Analysis By End Use
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET ANALYSIS BY FUNCTIONALITY

  • 5.1. Overview By Functionality
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Functionality
  • 5.4. Case Data Collection and Management Historic and Forecast Sales By Regions
  • 5.5. Adverse Event Reporting and Analysis Historic and Forecast Sales By Regions
  • 5.6. Signal Detection and Other Safety Risk Assessment Historic and Forecast Sales By Regions

6. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET ANALYSIS BY DELIVERY MODE

  • 6.1. Overview By Delivery Mode
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Delivery Mode
  • 6.4. On Premise Historic and Forecast Sales By Regions
  • 6.5. On Demand Historic and Forecast Sales By Regions

7. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET ANALYSIS BY END USE

  • 7.1. Overview By End Use
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By End Use
  • 7.4. Healthcare Companies (Pharmaceuticals & Biotechnology Companies) Historic and Forecast Sales By Regions
  • 7.5. CROs/BPOs or PV Service Providers When Outsourced. Historic and Forecast Sales By Regions
  • 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE COMPANIES

  • 9.1. Pharmacovigilance and Drug Safety Software Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. IQVIA
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Accenture
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Cognizant
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Laboratory Corporation Of America Holdings
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. IBM
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. ArisGlobal
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. ICON Plc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Capgemini
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Oracle
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Parexel International Corporation
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦